Sherry S
Department of Medicine, Temple University School of Medicine, Philadelphia.
Drugs. 1987;33 Suppl 3:1-12. doi: 10.2165/00003495-198700333-00002.
This paper deals with the history of thrombolytic therapy from its inception to its application in acute myocardial infarction. It describes the discovery of streptococcal fibrinolysin, followed by the elucidation of the plasma proteolytic enzyme system concerned with fibrinolysis. An outline is given of the therapeutic basis for the decision to concentrate on the development of activators of the enzyme, rather than the enzyme itself. Early attempts to demonstrate the value of streptokinase and urokinase in the treatment of myocardial infarction are examined. Finally, the more encouraging approaches in current use, especially the early application of thrombolytic therapy after the onset of the morbid event, are discussed.
本文论述了溶栓疗法从起源到在急性心肌梗死中的应用的历史。它描述了链球菌纤维蛋白溶酶的发现，随后阐明了与纤维蛋白溶解有关的血浆蛋白水解酶系统。概述了决定专注于酶激活剂而非酶本身开发的治疗依据。研究了早期证明链激酶和尿激酶在治疗心肌梗死中的价值的尝试。最后，讨论了当前使用的更令人鼓舞的方法，特别是在发病事件发生后早期应用溶栓疗法。
